Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

β1 integrins mediate the BMP2 dependent transcriptional control of osteoblast differentiation and osteogenesis.

Brunner M, Mandier N, Gautier T, Chevalier G, Ribba AS, Guardiola P, Block MR, Bouvard D.

PLoS One. 2018 Apr 20;13(4):e0196021. doi: 10.1371/journal.pone.0196021. eCollection 2018.

2.

β1 integrin-dependent Rac/group I PAK signaling mediates YAP activation of Yes-associated protein 1 (YAP1) via NF2/merlin.

Sabra H, Brunner M, Mandati V, Wehrle-Haller B, Lallemand D, Ribba AS, Chevalier G, Guardiola P, Block MR, Bouvard D.

J Biol Chem. 2017 Nov 24;292(47):19179-19197. doi: 10.1074/jbc.M117.808063. Epub 2017 Sep 29.

PMID:
28972170
3.

Correction: ICAP-1 monoubiquitylation coordinates matrix density and rigidity sensing for cell migration through ROCK2-MRCKα balance.

Bouin AP, Kyumurkov A, Régent-Kloeckner M, Ribba AS, Faurobert E, Fournier HN, Bourrin-Reynard I, Manet-Dupé S, Oddou C, Balland M, Planus E, Albiges-Rizo C.

J Cell Sci. 2017 Mar 15;130(6):1195. doi: 10.1242/jcs.202218. No abstract available.

4.

ICAP-1 monoubiquitylation coordinates matrix density and rigidity sensing for cell migration through ROCK2-MRCKα balance.

Bouin AP, Kyumurkov A, Régent-Kloeckner M, Ribba AS, Faurobert E, Fournier HN, Bourrin-Reynard I, Manet-Dupé S, Oddou C, Balland M, Planus E, Albiges-Rizo C.

J Cell Sci. 2017 Feb 1;130(3):626-636. doi: 10.1242/jcs.200139. Epub 2017 Jan 3. Erratum in: J Cell Sci. 2017 Mar 15;130(6):1195.

5.

Calcium and calmodulin-dependent serine/threonine protein kinase type II (CaMKII)-mediated intramolecular opening of integrin cytoplasmic domain-associated protein-1 (ICAP-1α) negatively regulates β1 integrins.

Millon-Frémillon A, Brunner M, Abed N, Collomb E, Ribba AS, Block MR, Albigès-Rizo C, Bouvard D.

J Biol Chem. 2013 Jul 12;288(28):20248-60. doi: 10.1074/jbc.M113.455956. Epub 2013 May 28.

6.

Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study.

Eikenboom J, Hilbert L, Ribba AS, Hommais A, Habart D, Messenger S, Al-Buhairan A, Guilliatt A, Lester W, Mazurier C, Meyer D, Fressinaud E, Budde U, Will K, Schneppenheim R, Obser T, Marggraf O, Eckert E, Castaman G, Rodeghiero F, Federici AB, Batlle J, Goudemand J, Ingerslev J, Lethagen S, Hill F, Peake I, Goodeve A.

J Thromb Haemost. 2009 Aug;7(8):1304-12. doi: 10.1111/j.1538-7836.2009.03486.x. Epub 2009 Jun 30.

7.

Molecular characterization of four ADAMTS13 mutations responsible for congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome).

Hommais A, Rayes J, Houllier A, Obert B, Legendre P, Veyradier A, Girma JP, Ribba AS.

Thromb Haemost. 2007 Sep;98(3):593-9.

PMID:
17849048
8.

Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13.

Rayes J, Hommais A, Legendre P, Tout H, Veyradier A, Obert B, Ribba AS, Girma JP.

J Thromb Haemost. 2007 Feb;5(2):321-8. Epub 2006 Nov 1.

9.

Impaired dimerization of von Willebrand factor subunit due to mutation A2801D in the CK domain results in a recessive type 2A subtype IID von Willebrand disease.

Hommais A, Stépanian A, Fressinaud E, Mazurier C, Pouymayou K, Meyer D, Girma JP, Ribba AS.

Thromb Haemost. 2006 May;95(5):776-81.

PMID:
16676067
10.

Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children.

Loirat C, Veyradier A, Girma JP, Ribba AS, Meyer D.

Semin Thromb Hemost. 2006 Mar;32(2):90-7. Review.

PMID:
16575683
11.

Mutations C1157F and C1234W of von Willebrand factor cause intracellular retention with defective multimerization and secretion.

Hommais A, Stépanian A, Fressinaud E, Mazurier C, Meyer D, Girma JP, Ribba AS.

J Thromb Haemost. 2006 Jan;4(1):148-57.

12.

Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome).

Veyradier A, Lavergne JM, Ribba AS, Obert B, Loirat C, Meyer D, Girma JP.

J Thromb Haemost. 2004 Mar;2(3):424-9.

13.

An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation.

Lenting PJ, Westein E, Terraube V, Ribba AS, Huizinga EG, Meyer D, de Groot PG, Denis CV.

J Biol Chem. 2004 Mar 26;279(13):12102-9. Epub 2003 Nov 12.

14.

A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease.

Stepanian A, Ribba AS, Lavergne JM, Fressinaud E, Juhan-Vague I, Mazurier C, Girma JP, Meyer D.

Br J Haematol. 2003 Feb;120(4):643-51.

PMID:
12588351
15.

Two clusters of charged residues located in the electropositive face of the von Willebrand factor A1 domain are essential for heparin binding.

Rastegar-Lari G, Villoutreix BO, Ribba AS, Legendre P, Meyer D, Baruch D.

Biochemistry. 2002 May 28;41(21):6668-78.

PMID:
12022870
16.

Identification of a new type 2M von Willebrand disease mutation also at position 1324 of von Willebrand factor.

Hilbert L, Fressinaud E, Ribba AS, Meyer D, Mazurier C; INSERM network on molecular abnormalities in von Willebrand disease.

Thromb Haemost. 2002 Apr;87(4):635-40.

PMID:
12008946
17.
18.

Defect of heparin binding in plasma and recombinant von Willebrand factor with type 2 von Willebrand disease mutations.

Rastegar-Lari G, Ajzenberg N, Ribba AS, Vereycken-Holler V, Legendre P, Villoutreix B, Meyer D, Baruch D.

Thromb Haemost. 2001 Dec;86(6):1459-65.

PMID:
11776314
19.

Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function.

Meyer D, Fressinaud E, Hilbert L, Ribba AS, Lavergne JM, Mazurier C.

Best Pract Res Clin Haematol. 2001 Jun;14(2):349-64. Review.

PMID:
11686104
20.

Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen.

Ribba AS, Loisel I, Lavergne JM, Juhan-Vague I, Obert B, Cherel G, Meyer D, Girma JP.

Thromb Haemost. 2001 Sep;86(3):848-54.

PMID:
11583318
21.
22.

Effect of recombinant von Willebrand factor reproducing type 2B or type 2M mutations on shear-induced platelet aggregation.

Ajzenberg N, Ribba AS, Rastegar-Lari G, Meyer D, Baruch D.

Blood. 2000 Jun 15;95(12):3796-803.

23.

Regulated von Willebrand factor (vWf) secretion is restored by pro-vWf expression in a transfectable endothelial cell line.

Rosnoblet C, Ribba AS, Wollheim CB, Kruithof EK, Vischer UM.

Biochim Biophys Acta. 2000 Jan 10;1495(1):112-9.

24.

New assay for measuring binding of platelet glycoprotein IIb/IIIa to unpurified von Willebrand factor.

Veyradier A, Jumilly AL, Ribba AS, Obert B, Houllier A, Meyer D, Girma JP.

Thromb Haemost. 1999 Jul;82(1):134-9.

PMID:
10456467
25.

Molecular genetics of von Willebrand disease.

Mazurier C, Ribba AS, Gaucher C, Meyer D.

Ann Genet. 1998;41(1):34-43. Review.

PMID:
9599650
26.

[Biological diagnosis of Willebrand disease].

Siguret V, Ribba AS, Meyer D.

Ann Biol Clin (Paris). 1997 Nov-Dec;55(6):601-6. French. No abstract available.

27.

Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. INSERM Network on Molecular Abnormalities in von Willebrand Disease.

Meyer D, Fressinaud E, Gaucher C, Lavergne JM, Hilbert L, Ribba AS, Jorieux S, Mazurier C.

Thromb Haemost. 1997 Jul;78(1):451-6. Review.

PMID:
9198195
28.

Primary structure of the propeptide and factor VIII-binding domain of bovine von Willebrand factor.

Janel N, Ribba AS, Chérel G, Kerbiriou-Nabias D, Meyer D.

Biochim Biophys Acta. 1997 Apr 25;1339(1):4-8.

PMID:
9165093
29.

Characterization of recombinant von Willebrand factors mutated on cysteine 509 or 695.

Siguret V, Ribba AS, Christophe O, Chérel G, Obert B, Rouault C, Nishikubo T, Meyer D, Girma JP, Piétu G.

Thromb Haemost. 1996 Sep;76(3):453-9.

PMID:
8883286
30.

Structure-function relationship of the A1 domain of von Willebrand factor.

Girma JP, Ribba AS, Meyer D.

Thromb Haemost. 1995 Jul;74(1):156-60.

PMID:
8578449
31.

Influence of mutations and size of multimers in type II von Willebrand disease upon the function of von Willebrand factor.

Christophe O, Ribba AS, Baruch D, Obert B, Rouault C, Niinomi K, Piétu G, Meyer D, Girma JP.

Blood. 1994 Jun 15;83(12):3553-61.

32.

Epitope mapping of inhibitory monoclonal antibodies to human von Willebrand factor by using recombinant cDNA libraries.

Piétu G, Ribba AS, Chérel G, Siguret V, Obert B, Rouault C, Ginsburg D, Meyer D.

Thromb Haemost. 1994 Jun;71(6):788-92.

PMID:
7974349
33.

Effect of plasmid size on transformation efficiency by electroporation of Escherichia coli DH5 alpha.

Siguret V, Ribba AS, Chérel G, Meyer D, Piétu G.

Biotechniques. 1994 Mar;16(3):422-6. No abstract available.

PMID:
8185915
34.

Discrepancy between IIA phenotype and IIB genotype in a patient with a variant of von Willebrand disease.

Ribba AS, Christophe O, Derlon A, Cherel G, Siguret V, Lavergne JM, Girma JP, Meyer D, Pietu G.

Blood. 1994 Feb 1;83(3):833-41.

35.
36.

Functional analysis of the Arg91Gln substitution in the factor VIII binding domain of von Willebrand factor demonstrates variable phenotypic expression.

Lavergne JM, Piao Y, Ribba AS, Girma JP, Siguret V, Piétu G, Boyer-Neumann C, Schandelong A, Bahnak BR, Meyer D.

Thromb Haemost. 1993 Oct 18;70(4):691-6.

PMID:
8115998
37.

Characterization of recombinant von Willebrand factor corresponding to mutations in type IIA and type IIB von Willebrand disease.

Ribba AS, Voorberg J, Meyer D, Pannekoek H, Pietu G.

J Biol Chem. 1992 Nov 15;267(32):23209-15.

38.
39.

Molecular study of von Willebrand disease: identification of potential mutations in patients with type IIA and type IIB.

Piétu G, Ribba AS, de Paillette L, Chérel G, Lavergne JM, Bahnak BR, Meyer D.

Blood Coagul Fibrinolysis. 1992 Aug;3(4):415-21.

PMID:
1420817
42.

Supplemental Content

Support Center